PIOLAX,INC. (5988) Stock Price

Piolax is primarily engaged in the manufacturing and sales of automotive-related products. The company operates globally with 16 subsidiaries and 1 affiliated company both domestically and internationally. Its main products include industrial fasteners and precision springs, which are used in vehicle interiors and exteriors.

Domestically, Piolax HFS, PNS, Piolax Kyushu, and K&K handle manufacturing and supply products to automotive manufacturers including Nissan Motor. Additionally, KHK Sales handles sales to small-volume customers. Piolax Business Service manages accounting, human resources, and general affairs operations.

Internationally, the company manufactures and sells automotive components in Georgia (USA), Lancashire (UK), Incheon (South Korea), Rayong (Thailand), Guangdong and Hubei (China), Andhra Pradesh (India), Nuevo León (Mexico), and West Java (Indonesia). Through these operations, the company supplies products to automotive manufacturers in each region.

In the medical device sector, Piolax Medical Devices manufactures and sells medical-related products. Additionally, Piolax has established a business partnership with Saga Ironworks, a leading manufacturer of automotive bolts, to build global cooperation. However, in February 2025, the company sold a portion of Saga Ironworks' shares and excluded it from the scope of equity method accounting.

Piolax is pursuing sustainable growth through innovative strategies. The "Piolax Way," established to commemorate the company's 90th anniversary, aims to connect people and society through technology and create new value. Under this vision, the company is shifting away from dependence on automotive production volumes and focusing on developing high-value-added products that leverage its technological capabilities.

The company is particularly investing in advanced driver assistance systems (ADAS)-related products, batteries, and busbars for e-axles. Centered on its new Moka plant, Piolax is actively expanding equipment investment, including the introduction of large-scale molding machines. As part of its regional growth strategy, the company is strengthening production capacity in India and expanding sales to non-Japanese automotive manufacturers.

Organizational restructuring is underway, with a transition to a function-based structure beginning in April 2025 to enable faster and more flexible business operations. This will accelerate strategy formulation and execution, optimize resource allocation, and enhance corporate value. In the medical device business, the company is focusing on minimally invasive treatments and strengthening product planning and sales capabilities through collaborative research with university hospitals.

Sustainability initiatives are also prioritized, with "PIOLAX ESG Vision 2030" guiding efforts toward a decarbonized and circular economy. The company is reviewing its capital policy to improve capital efficiency and corporate value through share buybacks and continued dividend payments. Through these strategies, Piolax is pursuing sustainable growth.